In the field of ovarian cancer, activation of PPAR-α has been involved with suppression of the hypoxia-inducible factor 1 alpha (HIF-1a), a process that was confirmed following the use of proteasome inhibitors, which reversed this process [34]. Here, PPARA is linked to ovarian carcinoma.